Fhit protein expression in lung cancer studied by high-throughput tissue microarray.

Area of Science:

• Oncology
• Molecular Pathology
• Cancer Biomarkers

Background:

• The Fhit (Fragile Histidine Triad) gene acts as a tumor suppressor.
• Altered Fhit protein expression is implicated in various cancers, including lung cancer.
• Understanding Fhit expression patterns is crucial for lung cancer diagnosis and prognosis.

Purpose of the Study:

• To investigate the expression levels of Fhit protein in lung cancer tissues.
• To determine the association between Fhit protein expression and clinicopathological features of lung cancer.
• To evaluate the utility of tissue microarrays for assessing Fhit protein expression in lung cancer.

Main Methods:

• Utilized tissue microarrays (TMA) and immunohistochemistry (IHC) on 321 lung cancer cases.
• Assessed Fhit protein expression using the S-P immunohistochemistry method on TMAs.
• Analyzed Fhit protein expression in relation to histological subtypes, smoking status, and patient demographics.

Main Results:

• Fhit protein expression was lost or significantly reduced in 67.1% of evaluable lung cancer cases (170/253).
• Loss of Fhit expression was more prevalent in small cell lung cancers (SCLCs) than non-small cell lung cancers (NSCLCs).
• Higher frequency of Fhit loss was observed in squamous cell carcinomas compared to adenocarcinomas, and in tumors from smokers and males.

Conclusions:

• Reduced or lost Fhit protein expression is a common event in lung cancers, with distinct patterns across histological subtypes.
• Fhit expression loss is significantly more frequent in smokers, suggesting a role in smoking-related lung carcinogenesis.
• Tissue microarrays provide an efficient platform for evaluating tumor markers like Fhit protein in large cohorts.